Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Adolescent Substance Abuse: Progressive Treatment (ADAPT)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Oregon Research Institute
ClinicalTrials.gov Identifier:
NCT00680576
First received: May 16, 2008
Last updated: October 8, 2014
Last verified: October 2014
  Purpose

The purpose of this study is to find out more about how to provide effective further treatment for adolescents who have received six weeks of group therapy for substance-use problems and continue to use drugs. Treatments used in the study include a group therapy (MET/CBT), an individual therapy (CBT), and a family therapy (FFT). The study will look at whether abstinence or a very low level of use is a better guide for deciding whether further treatment is needed, how well different combinations of treatment work to reduce substance use, and whether it is possible to predict in advance which adolescents will respond best to which types of treatment. Study investigators expect that a treatment strategy using what is learned about these issues in the first half of the project to develop an "adaptive" treatment model will work better than a "fixed" treatment to reduce adolescent substance use.


Condition Intervention Phase
Substance Abuse
Behavioral: CBT, Cognitive Behavioral Therapy
Behavioral: FFT, Family Functional Therapy
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Treatment

Further study details as provided by Oregon Research Institute:

Primary Outcome Measures:
  • Urine drug screens [ Time Frame: Pretx, 6, 14 and 22 weeks, 3 and 6 months after initial treatment session ] [ Designated as safety issue: No ]

Enrollment: 140
Study Start Date: March 2008
Study Completion Date: August 2013
Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Eight weeks of individual CBT for adolescents who have completed six weeks of group therapy and continue to use drugs.
Behavioral: CBT, Cognitive Behavioral Therapy
Eight weekly sessions of individual Cognitive Behavioral Therapy, to develop skills enabling adolescents stop or reduce their drug use.
Active Comparator: 2
Eight weeks of FFT for adolescents who have received six weeks of group therapy and continue to use drugs.
Behavioral: FFT, Family Functional Therapy
Eight weekly sessions of Functional Family Therapy designed to strengthen family relationships and build skills to help the adolescent stop or reduce his/her drug use.

  Eligibility

Ages Eligible for Study:   13 Years to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. 13 to 18 years if age
  2. Meet DSM-IV (APA, 1994) diagnostic criteria for substance abuse or dependence
  3. Live in the Albuquerque metropolitan area or surrounding communities
  4. Sufficient residential stability to permit probable contact at follow-up (e.g., not homeless at time of intake).

Exclusion Criteria:

  1. There is evidence of psychotic or organic state of sufficient severity to interfere with the understanding of study instruments and procedures
  2. The adolescent is deemed dangerous to self or others during evaluation
  3. Services other than outpatient treatment are required for the adolescent (e.g., inpatient, detoxification)
  4. Marijuana use is reported as being less than 13% of days in the previous 90 days.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00680576

Locations
United States, New Mexico
Oregon Res. Inst. Center for Family & Adolescent Research (CFAR)
Albuquerque, New Mexico, United States, 87102
Sponsors and Collaborators
Oregon Research Institute
Investigators
Principal Investigator: Holly B Waldron, Ph.D. Oregon Research Institute Center for Family and Adolescent Research (ORI/CFAR)
  More Information

No publications provided

Responsible Party: Oregon Research Institute
ClinicalTrials.gov Identifier: NCT00680576     History of Changes
Other Study ID Numbers: DA023568, R01DA023568
Study First Received: May 16, 2008
Last Updated: October 8, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Oregon Research Institute:
adolescent substance abuse

Additional relevant MeSH terms:
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders

ClinicalTrials.gov processed this record on November 20, 2014